Intermediate Outcome and Risk Factor Assessment of Bovine Vascular Heterografts used as AV-Fistulas for Hemodialysis Access

Abstract

ProCol grafts, used for AV-fistulas, demonstrate acceptable patency rates in high-risk haemodialysis patients. Diabetes mellitus jeopardizes the patency of these fistulas and is associated with a high revision rate.

The use of three-dimensional nanostructures to instruct cells to produce extracellular matrix for regenerative medicine strategies

“…As demonstrated by our previous work, exposing the electrospun scaffolds to a cross-linker such as glutaraldehyde, intermolecularly cross-links the scaffolds, making cell-culturing possible; however, the use of glutaraldehyde also reduces porosity dramatically [10], and glutaraldehyde-treated biomaterials can be cytotoxic [43]. Moreover, results from clinical studies have shown that treatment with glutaraldehyde can cause vascular graft failure related to aneurysm formation, calcification and infection [44-46]. In order to avoid the need for cross-linking agents, sheet-ECM proteins were stabilized using PCL.…”

Randomized clinical trial comparing decellularized bovine ureter with expanded polytetrafluoroethylene for vascular access

“…Previous reports of survival after ePTFE graft implantation range from 53 to 96 per cent 20,21 compared with 62 per cent for biological grafts 22 . Another xenograft conduit, the ProCol  bovine mesenteric vein graft (Hancock Jaffe Laboratories, Irvine, California, USA) had patient survival rates of 77 and 86 per cent 23,24 . The present patient survival of 86 per cent in the SG 100 group compared favourably with 84 per cent reported by Darby and co-workers 12 .…”

Diagnostic Imaging of and Radiologic Intervention for Bovine Ureter Grafts Used as a Novel Conduit for Hemodialysis Fistulas

“…To our knowledge, only one other recent study has been published about the mediumterm outcome of bioprostheses used as hemodialysis fistulas [8]. None of the patients in that study underwent reported interventional radiologic procedures to salvage dysfunctional grafts.…”

“…A study of 62 bioprosthetic hemodialysis fistulas manufactured from denatured bovine mesenteric veins followed up over a mean period of 453 days showed a secondary patency rate of 73% at 6 months [8]. The authors of that study concluded that these denatured bovine xenografts could be used as conduits for hemodialysis fistulas with reasonable results in high-risk patients without autogenous veins.…”